You are offline. Saved alerts are still available. Live updates resume when you reconnect.
Reading a stock page
- The tabs show the price chart, results, shareholding, events and news for this one company.
- The Signal Score sums up trend, momentum and quality from past data. It is a description, not a forecast.
- Every figure names its source. "Official" means it came from NSE or BSE filings.
- Use the star to watch the stock, or Add to portfolio to record a trade.
🎯 Buy It or Not? — Complete Intraday to Long-Term Decision Report for ONESOURCE (NSE)
Official NSE & BSE Auto-Sync: Checking Overview, Financials, Technicals, Shareholding & Events in the background...
69
ISA Signal Score: Positive
Trend78
Momentum77
52-week range66
Volume65
Risk59
Fundamentals60
Working for it
- Price is above its 20-day average
- Price is above its 50-day average
- Price is above its 200-day average (long-term uptrend)
- RSI 59: healthy strength
- Low debt
Working against it
- 50-day average is below the 200-day average
- Revenue fell 2% year on year
At a glance
QualityWeakROE -1.3%, ROCE 0.4%, debt 0.22x equity
GrowthFastSales 81.2% a year over 4 years
ValuationNo earningsP/E cannot be worked out while the company makes a loss.
MomentumMixedAbove its 200-day average, lagged NIFTY 50 by 2.3 points
RiskMediumSwings 45% a year, fell up to 38% from a peak, beta -0.11
Smart Investor Tips: ONESOURCE
Caution Warranted (Trend or Balance-Sheet Headwinds)Actionable Insights & Positives
- Tip: Click the star button above to add this stock to your Watchlist and set a target "Buy below" alert price.
Risk Checks & Things to Verify
- Reported a net loss in FY26. Turnaround stories carry higher execution risk.
- High 30-day annualized volatility (49%). Keep initial position sizes smaller and use wider stop-review levels.
NSE MCP Live & 5-Year Check No API Key
Algorithmic Momentum Prediction & Optimal Entry PriceWEAK / REDUCE ON BOUNCES (Score 25/100)
Weak trend, debt overhang, or distribution. Avoid fresh buying until price reclaims 50-DMA (Rs 1,538.54). If already held, protect capital if it breaks below Rs 1,435.63 or trim near resistance Rs 1,688.00.
| Optimal Support area | Tranche 1 (50%) | Tranche 2 (50%) | Risk level / Review | Level 1 (Swing) | Level 2 (Breakout) | Risk : Reward |
|---|---|---|---|---|---|---|
| Rs 1,515.46 – Rs 1,593.21 Ideal ~Rs 1,554.34 |
Rs 1,593.21 | Rs 1,515.46 | Rs 1,435.63 ATR 3.3% |
Rs 1,768.02 | Rs 1,917.80 | 1 : 1.8 RSI 61 · Vol 1.34x |
Live Candlestick & TradingView Chart (ONESOURCE)
MARKET CLOSED - EOD SNAPSHOTKey figures
P/E-loss making
P/B-price / book value
EPSRs -6.44earnings per share
Dividend yield-from saved dividend events
Debt to equity0.22xnet debt Rs 1,276 Cr
Sales growth81.2%a year over 4 years
Profit growth-yearly, needs 2+ years
Operating margin21.4%net margin -5.2%
Company Debt, Borrowings & Cash Flow Health
Total Debt / Loans
Rs 1,276 Cr
Increased +Rs 504 Cr YoY
Cash & Bank Balances
-
Liquid cash & equivalents
Net Debt (Loans − Cash)
Rs 1,276 Cr
15.4% of total assets
Debt to Equity & Interest Cover
0.22x D/E
Interest cover: 0.2x EBIT
Operating Cash Flow (OCF)
Rs 9.00 Cr
Cash generated from operations
Free Cash Flow (FCF)
-
OCF minus Capex
About ONESOURCE SPECL PHARMA L
Pharma & HealthcareMarket capNot available
First listed24 Jan 2025BSE not available · NSE 24 Jan 2025
Face valueRs 1
Book valueNot available
ROENot availableReturn on equity
ROCENot availableReturn on capital employed
Profile completeness3 of 8Missing: description, share count, book value, ROE, ROCE
Shareholding
Promoters and group 30.47% -0.01 pp, public 69.53%, as on 30 Sep 2026. Holder names and history
Day range1,574.30 to 1,621.90Open 1,585.00
52-week high1,917.80
-16.1% from high (18 May 2026)
52-week low1,057.00
+52.3% from low (30 Jan 2026)
Volume1.79 L
0.2x the 20-day average
RSI (14)59
neutral
Volatility (30d)48.6%annualised
Returns
1W-0.0%
1M+18.6%
3M+4.8%
6M-12.3%
1Y-3.8%
YTD-11.1%
Against the NIFTY 50
| Period | ONESOURCE | NIFTY 50 | Difference |
|---|---|---|---|
| 1M | +18.6% | +13.1% | +5.5 pts |
| 3M | +4.8% | +6.4% | -1.5 pts |
| 6M | -12.3% | +8.8% | -21.1 pts |
| 1Y | -3.8% | -1.5% | -2.3 pts |
Risk over the past year
Volatility45%medium
Deepest fall-38.5%from a peak
Beta-0.11moves less than the index
Best day+13.8%27 Oct 2026
Worst day-19.6%27 Jan 2026
Up days48%of sessions
🛡 Forensic Financial Health: Piotroski F-Score & 3-Step DuPont ROE Decomposition
Piotroski F-Score: 3 / 9 · Weak / Watch Balance Sheet
3-Step DuPont ROE Identity:
Balanced Profitability & Efficiency
Net Margin: -5.2%
×
Asset Turnover: 0.17x
×
Equity Multiplier: 1.42x
=
ROE -1.3%
⚠ Positive Net Profit (PAT > 0)
Rs -74.0 Cr
✓ Positive Operating Cash Flow (OCF > 0)
Rs 9.00 Cr
⚠ High Cash Conversion (OCF >= 85% of PAT)
N/A
⚠ Improving Return on Assets (ROA YoY)
-0.9% vs -0.2%
✓ Conservative / Decreasing Debt-to-Equity
0.22x (prev 0.13x)
✓ Healthy Balance Sheet Asset Coverage
6.94x
⚠ Institutional Return on Equity (ROE >= 14%)
-1.3%
⚠ Stable / Expanding Profit Margin YoY
-5.2% vs -1.2%
⚠ Asset Turnover Efficiency (Sales / Assets)
0.17x
Quarterly Results (Last 8 Quarters — QoQ & YoY Acceleration)
| Rs crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales / Revenue | 393 | 426 | 327 | 376 | 290 | 428 | 449 | 516 |
| Sales QoQ % | +17.7% | +8.4% | -23.2% | +15.0% | -22.9% | +47.6% | +4.9% | +14.9% |
| Operating Profit | 142 | 182 | 89.0 | 107 | 17.0 | 93.0 | 123 | 164 |
| Operating Margin (OPM %) | 36.1% | 42.7% | 27.2% | 28.5% | 5.9% | 21.7% | 27.4% | 31.8% |
| Net Profit (PAT) | -69.0 | 98.0 | 0 | 10.0 | -89.0 | 5.00 | 25.0 | 57.0 |
| Profit QoQ % | -64.3% | +242.0% | -100.0% | - | -990.0% | +105.6% | +400.0% | +128.0% |
| Profit YoY % | +46.9% | +345.0% | +100.0% | +123.8% | -29.0% | -94.9% | - | +470.0% |
| Net Margin % | -17.6% | 23.0% | 0.0% | 2.7% | -30.7% | 1.2% | 5.6% | 11.0% |
Sales and profit
Sales growth+81.2%a year, 4Y
Profit growth-a year, 4Y
EPS growth-a year, 4Y
Avg ROE-36.0%5 years
Profit and loss
| Rs crore | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales | 132 | 39.0 | 172 | 1,445 | 1,422 |
| Sales growth | - | -70.5% | +341.0% | +740.1% | -1.6% |
| Operating profit | -97.0 | -160 | -83.0 | 466 | 304 |
| Operating margin | -73.5% | -410.3% | -48.3% | 32.2% | 21.4% |
| Other income | 4.00 | -526 | -143 | -94.0 | 5.00 |
| Interest | 68.0 | 48.0 | 89.0 | 166 | 122 |
| Depreciation | 70.0 | 66.0 | 76.0 | 274 | 279 |
| Profit before tax | -231 | -800 | -391 | -68.0 | -92.0 |
| Tax rate | - | - | - | - | - |
| Net profit | -231 | -800 | -391 | -18.0 | -74.0 |
| Profit growth | - | - | - | - | - |
| Net margin | -175.0% | -2,051.3% | -227.3% | -1.2% | -5.2% |
| EPS (Rs) | - | - | - | -1.57 | -6.44 |
Balance sheet
| Rs crore | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Equity (net worth) | 1,012 | 785 | 396 | 5,880 | 5,831 |
| Borrowings | 1,154 | 864 | 562 | 772 | 1,276 |
| Cash | - | - | - | - | - |
| Total assets | 2,442 | 2,015 | 1,426 | 7,657 | 8,304 |
| Debt to equity | 1.14x | 1.10x | 1.42x | 0.13x | 0.22x |
Debt, Loans, Cash Flow & Working Capital
| Rs crore | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Operating Cash Flow (OCF) | -416 | -163 | -107 | -68.0 | 9.00 |
| Capital Expenditure (Capex) | - | - | - | - | - |
| Free Cash Flow (FCF = OCF - Capex) | - | - | - | - | - |
| OCF / Net Profit Conversion | - | - | - | - | - |
| Total Borrowings / Loans | 1,154 | 864 | 562 | 772 | 1,276 |
| Cash & Bank Balances | - | - | - | - | - |
| Trade Receivables (Cr) | - | - | - | - | - |
| Receivable Days | - | - | - | - | - |
| Inventories (Cr) | - | - | - | - | - |
| Inventory Days | - | - | - | - | - |
Returns on capital
| Rs crore | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE | -22.8% | -89.0% | -66.2% | -0.6% | -1.3% |
| ROCE | -7.5% | -39.4% | -23.2% | 2.6% | 0.4% |
| Interest cover | -2.40x | -15.67x | -3.39x | 0.59x | 0.25x |
Compared with its sector Pharma & Healthcare
| Stock | Price | Day | 1 year | Mkt cap (Cr) | P/E | P/B | ROE | Net margin |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMASUN PHARMACEUTICAL IND L | 1,884.90 | -0.8% | - | 452,244 | 39.4 | - | 15.0% | 19.7% |
| TORNTPHARMTORRENT PHARMACEUTICALS L | 4,689.50 | +1.7% | - | 158,505 | 74.2 | - | 24.2% | 15.3% |
| LAURUSLABSLAURUS LABS LIMITED | 2,294.60 | -0.5% | - | 123,667 | 139.4 | 23.3 | 16.8% | 13.1% |
| ZYDUSLIFEZYDUS LIFESCIENCES LTD | 1,200.00 | -0.2% | - | 120,720 | 24.0 | 4.5 | 18.9% | 18.9% |
| MANKINDMANKIND PHARMA LIMITED | 2,665.00 | +1.4% | - | 106,757 | 55.8 | 11.4 | 20.4% | 18.5% |
| MAXHEALTHMAX HEALTHCARE INS LTD | 1,081.00 | +3.9% | - | 105,063 | 72.9 | 9.8 | 13.4% | 17.2% |
| LUPINLUPIN LIMITED | 2,014.00 | +0.8% | - | 91,778 | 17.3 | - | 13.4% | 19.2% |
| GLENMARKGLENMARK PHARMACEUTICALS | 2,648.00 | +1.5% | - | 74,724 | - | 9.5 | -19.1% | -12.7% |
| FORTISFORTIS HEALTHCARE LTD | 825.00 | +1.9% | - | 62,284 | 59.8 | - | 7.8% | 11.7% |
| GLANDGLAND PHARMA LIMITED | 3,331.90 | +1.2% | - | 54,880 | 53.4 | - | 8.9% | 16.0% |
| IPCALABIPCA LABORATORIES LTD | 1,843.80 | -0.9% | - | 46,777 | 41.0 | 5.8 | 14.7% | 12.3% |
| GLAXOGLAXOSMITHKLINE PHARMA LT | 2,727.60 | +0.5% | - | 46,208 | 78.3 | 26.0 | 33.2% | 17.1% |
| ONESOURCEONESOURCE SPECL PHARMA L | 1,609.30 | +0.4% | - | - | - | - | -1.3% | -5.2% |
| Sector median | - | 54.7 | 6.7 | 13.8% |
Today: 15 minute chart and signal
Analysis and next-session reading
Signals
Price is above its 50-day average
20-day average is above the 50-day (short-term uptrend)
Price is above its 200-day average (long-term uptrend)
RSI 59: neutral
When is a good price?
The price is in the upper half of its 1-year range and is lower than it was on 43% of days in the past year.
Support (prices below today's)
| 200-day average | 1,553.35 | -3.5% |
| 50-day average | 1,538.54 | -4.4% |
| 20-day low | 1,320.60 | -17.9% |
| 60-day low | 1,320.60 | -17.9% |
| 52-week low | 1,057.00 | -34.3% |
Resistance (prices above today's)
| 20-day high | 1,688.00 | +4.9% |
| 60-day high | 1,688.00 | +4.9% |
| 52-week high | 1,917.80 | +19.2% |
Zones buyers often watch
| Lower quarter of the 1-year range | 1,057.00 to 1,272.20 | Historically the cheapest part of the past year. |
| Pullback of 10% to 20% from the high | 1,534.24 to 1,726.02 | price is inside this zone now |
| Around the 200-day average | 1,506.75 to 1,599.95 | Long-term trend line, often watched as support. |
Moving averages and momentum
| Indicator | Value | Reading |
|---|---|---|
| 20-day average | 1,567.27 | Price is 2.7% above |
| 50-day average | 1,538.54 | Price is 4.6% above |
| 200-day average | 1,553.35 | Price is 3.6% above |
| RSI (14) | 59 | Neutral |
| MACD (12, 26, 9) | 26.68 | Above its signal line (momentum rising) |
| Volatility (30d) | 48.6% | High yearly swings |
Support and resistance
R21,649.43
R11,629.37
Pivot1,601.83
S11,581.77
S21,554.23
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| 2026-11-20 | 1,585.00 | 1,621.90 | 1,574.30 | 1,609.30 | +0.40% | 178,590 |
| 2026-11-19 | 1,587.00 | 1,617.40 | 1,570.00 | 1,602.90 | +1.05% | 126,006 |
| 2026-11-18 | 1,580.80 | 1,592.40 | 1,563.40 | 1,586.20 | +0.34% | 159,423 |
| 2026-11-17 | 1,612.00 | 1,614.00 | 1,578.00 | 1,580.80 | -1.98% | 210,366 |
| 2026-11-16 | 1,615.00 | 1,650.00 | 1,587.80 | 1,612.70 | +0.16% | 311,345 |
| 2026-11-13 | 1,620.00 | 1,688.00 | 1,600.50 | 1,610.10 | -0.61% | 599,203 |
| 2026-11-12 | 1,583.10 | 1,635.10 | 1,577.10 | 1,620.00 | +2.42% | 277,501 |
| 2026-11-11 | 1,620.60 | 1,644.00 | 1,576.50 | 1,581.70 | -2.24% | 221,763 |
| 2026-11-09 | 1,624.60 | 1,649.80 | 1,609.50 | 1,618.00 | -0.89% | 165,587 |
| 2026-11-06 | 1,581.90 | 1,619.10 | 1,566.00 | 1,599.80 | +1.13% | 276,774 |
| 2026-11-05 | 1,610.00 | 1,644.00 | 1,569.90 | 1,581.90 | -0.11% | 654,875 |
| 2026-11-04 | 1,585.40 | 1,599.80 | 1,566.00 | 1,583.60 | +0.95% | 481,453 |
| 2026-11-03 | 1,569.00 | 1,575.10 | 1,535.50 | 1,568.70 | +0.67% | 318,991 |
| 2026-11-02 | 1,563.00 | 1,601.50 | 1,542.20 | 1,558.20 | -0.31% | 329,034 |
| 2026-10-30 | 1,574.80 | 1,600.00 | 1,540.90 | 1,563.00 | -0.42% | 954,663 |
| 2026-10-29 | 1,585.00 | 1,597.60 | 1,564.00 | 1,569.60 | -0.51% | 736,956 |
| 2026-10-28 | 1,620.00 | 1,642.90 | 1,560.00 | 1,577.60 | -0.77% | 3,811,761 |
| 2026-10-27 | 1,402.70 | 1,605.00 | 1,384.10 | 1,589.80 | +13.78% | 7,803,594 |
| 2026-10-26 | 1,334.10 | 1,404.50 | 1,326.10 | 1,397.30 | +4.74% | 228,373 |
| 2026-10-23 | 1,377.80 | 1,377.80 | 1,320.60 | 1,334.10 | -3.17% | 206,529 |
| 2026-10-22 | 1,358.00 | 1,385.30 | 1,326.30 | 1,377.80 | +1.53% | 108,051 |
| 2026-10-21 | 1,365.70 | 1,385.00 | 1,331.30 | 1,357.10 | -0.70% | 216,713 |
News from the last 15 days More
Events
2026
- 27OctFinancial ResultRelease date · NSE record
- 24JulQuarterly ResultRelease date · NSE record
- 13MayFinancial ResultRelease date · NSE record
- 23JanFinancial ResultRelease date · NSE record
2025
- 11NovFinancial ResultRelease date · NSE record
- 04AugQuarterly ResultRelease date · NSE record
- 05MayFinancial ResultRelease date · NSE record
- 29JanFinancial ResultRelease date · NSE record